Dova Pharmaceuticals Inc. (DOVA) Stock Price, Quote, News and Overview
NASDAQ:DOVA - Nasdaq -
DOVA Quote, Performance and Key Statistics
28.04
+0.04 (+0.14%)
The current stock price of DOVA is 28.04 null. In the past month the price decreased by -0.25%. In the past year, price increased by 80.9%.
About DOVA
Company Profile
Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina.
Company Info
Dova Pharmaceuticals Inc.
240 Leigh Farm Road Suite 245
Durham NC 27707
CEO: David Zaccardelli
Phone: 919-748-5975
Dova Pharmaceuticals Inc. / DOVA FAQ
What is the stock price of Dova Pharmaceuticals Inc. today?
The current stock price of DOVA is 28.04 null. The price increased by 0.14% in the last trading session.
What is the ticker symbol for Dova Pharmaceuticals Inc. stock?
The exchange symbol of Dova Pharmaceuticals Inc. is DOVA and it is listed on the Nasdaq exchange.
On which exchange is DOVA stock listed?
DOVA stock is listed on the Nasdaq exchange.
What is Dova Pharmaceuticals Inc. worth?
Dova Pharmaceuticals Inc. (DOVA) has a market capitalization of 807.61M null. This makes DOVA a Small Cap stock.
What are the support and resistance levels for Dova Pharmaceuticals Inc. (DOVA) stock?
Dova Pharmaceuticals Inc. (DOVA) has a support level at 28.03 and a resistance level at 28.14. Check the full technical report for a detailed analysis of DOVA support and resistance levels.
Should I buy Dova Pharmaceuticals Inc. (DOVA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DOVA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DOVA, evaluating the profitability, health, valuation and growth aspects
- Dova Pharmaceuticals Inc. (DOVA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Dova Pharmaceuticals Inc. (DOVA) Sales and EPS estimates to see what analysts future expectations are.
- Dova Pharmaceuticals Inc. (DOVA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Dova Pharmaceuticals Inc. (DOVA) Insider and Institutional Ownership to learn about the owners and their transactions.
- Dova Pharmaceuticals Inc. (DOVA) Stock Chart to make your own analysis
- Dova Pharmaceuticals Inc. (DOVA) Latest news and press-releases to stay up to date.
Does Dova Pharmaceuticals Inc. (DOVA) stock pay dividends?
DOVA does not pay a dividend.
What is the Price/Earnings (PE) ratio of Dova Pharmaceuticals Inc. (DOVA)?
Dova Pharmaceuticals Inc. (DOVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.56).
DOVA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DOVA. When comparing the yearly performance of all stocks, DOVA is one of the better performing stocks in the market, outperforming 98.83% of all stocks.
DOVA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DOVA. While DOVA seems to be doing ok healthwise, there are quite some concerns on its profitability.
DOVA Financial Highlights
Over the last trailing twelve months DOVA reported a non-GAAP Earnings per Share(EPS) of -2.5599999999999996. The EPS decreased by -30.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -539.32% | ||
| ROA | -93.81% | ||
| ROE | N/A | ||
| Debt/Equity | 0.9 |
DOVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to DOVA. The Buy consensus is the average rating of analysts ratings from 5 analysts.